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Abstract
GENERATION OF MACROPHAGE CHEMOTACTIC FACTORS BY sPLA2
By Andria Chambers, B.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Masters of 
Science  at Virginia Commonwealth University.
Virginia Commonwealth University, 2009
Major Director:  Suzanne E. Barbour, Ph.D.
Professor, Department of Biochemistry and Molecular Biology
Removal of apoptotic cells by macrophages is required in order to prevent autoimmune 
responses.  Previous studies have reported that group IIA secretory phospholipase A2 
(sPLA2) preferentially binds to apoptotic cells and induces a chemotactic factor which 
promotes the migration of macrophages to apoptotic cells.  Based on these observations, 
we hypothesized that the pool of sPLA2 trapped on apoptotic cells produces 
chemoattractant lipids that recruit macrophages to phagocytose the apoptotic cells.  To test 
this hypothesis, Jurkat cells were cultured under normal conditions and induced to undergo 
early apoptosis through treatment with D,L-threo-dihydrosphingosine.  Live and early 
apoptotic cells were incubated with catalytically active sPLA2 and then cell-associated 
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catalytic activity was assessed.  In contrast to previous reports, we observed no difference 
in the ability of live or early apoptotic cells to trap group IIA sPLA2 on their surfaces. 
However, transmigration assays involving THP-1 monocytes confirmed that the cell-bound 
pool of sPLA2 generates chemoattractants when bound to the surfaces of live cells. 
Surprisingly, sPLA2 does not have to be catalytically active to attract THP-1 monocytes. 
The treatment of live Jurkat cells with heparinase showed a marked reduction in the ability 
of sPLA2 to bind to live cells and exert catalytic activity, suggesting heparan sulfate 
proteoglycans are possibly receptors for sPLA2.  Future experiments are being planned to 
identify sPLA2 receptor(s) on THP-1 monocytes.  
viii
Introduction
Apoptosis, or programmed cell death, was given its distinct name in 1972 by John 
Kerr, Andrew Wilie, and Alastair Currie when they noticed distinct morphological changes 
observed in a wide variety of cell types that underwent a unique kind of cell death differing 
from necrosis (1).  Apoptosis occurs in all multi-cellular organisms and is usually seen 
during the development of infections, wound healing, or in diseased areas.  Apoptosis is 
characterized by many biochemical and morphological changes such as dramatic 
perturbations to the cellular architecture which contribute to cell death and prepare the 
dying cells for removal by phagocytes.  The removal by phagocytes prevents unwanted 
immune responses (2).  Some classic characteristics of apoptosis are cell shrinkage, DNA 
fragmentation, cytoplasmic condensation, dramatic condensation of nuclear 
heterochromatin, dislocation of the endoplasmic reticulum, cell surface blebbing, and loss 
of phospholipid asymmetry (1, 2). 
The best characterized change in cells undergoing apoptosis is the loss of 
phospholipid asymmetry and the translocation of phosphatidylserine (PS) from the inner 
leaflet of the phospholipid bilayer to the outer leaflet.  This process occurs very early in 
apoptosis and forms a signal to be recognized by phagocytes and other types of activated 
macrophages (3).  The PS exposure and ultimate recognition by phagocytes suggests that 
the lipid is not ordinarily seen on the plasma membrane surface.  PS makes up about 2-
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10% of the lipids in the plasma membrane in most eukaryotic cells, and in healthy cells 
nearly all of the PS is on the inner leaflet of the plasma membrane (5).  Phosphatidylserine 
is normally kept from the surface of T-lymphocytes by ATP dependent internalization 
mediated by an aminophospholipid translocase.  The enzyme has the unique ability to 
move phosphatidylserine and phosphatidylenolamine (with less efficiency) to the outer cell 
interior (4).  Down regulation of the translocase and activation of a lipid scramblase allows 
for PS exposure on the cell surface before DNA degradation, membrane blebbing, and cell 
lysis. Though PS exposure is very important, it may not necessarily be significant enough 
for uptake by phagocytosis; there are many changes in the expression of membrane 
associated markers.  Other kinds of recognition signals produced on the surface of 
apoptotic cells are exposure of a ligand for the vitronectin receptor; exposure of the 
phosphocholine functional group on membrane phosphatidylcholine; changes in the 
surface charge of the glycoproteins and lipids; binding of thrombospondin; and expression 
of intercellular adhesion molecule III (5).  Clearance of apoptotic cells is a complex 
process where many surface molecules, adaptors, and chemotactic molecules are involved 
but it is not necessary that all of the recognition signals are expressed or that all receptors 
are required to mediate engulfment.
The process of apoptotic cell engulfment can be divided into broad steps:  sensing 
the presence of the apoptotic cells; recognition of the apoptotic cells by the phagocyte; 
cytoskeletal reorganization and internalization of the target; processing and degradation of 
the ingested apoptotic cell; and post engulfment responses of the phagocyte (5). Apoptosis 
normally leads to swift engulfment by professional (macrophages and immature dendritic 
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cells) and non professional phagocytes (endothelial cells, fibroblasts, smooth cells, 
epithelial cells).  Certain receptors on activated macrophages such as phosphatidylserine 
receptors, CD14, lectins, integrins, asialoglycoprotein receptors, and more specifically a 
vitronectin receptor that cooperates with CD36 on human monocyte-derived macrophages 
which binds to thrombospondin on apoptotic cells (25).  These receptors in turn can assist 
in attracting phagocytes to apoptotic cells.   Phagocytes can engulf apoptotic cells and use 
a major histocompatibility complex anchored in the cell membrane to display the degraded 
polypeptides on their surface to T cells via T cell receptors. The MHC peptide complex 
binds with ligands for antigen receptors on T cells and regulates T cell activity (4). The 
surrounding tissues are protected from pro-inflammatory cell contents, such as TNF-α and 
IFN-γ.  The pro-inflammatory cell contents can ultimately leak and cause accidental cell 
death, or necrosis.  Apoptotic cells that are cleared promptly exhibit immune tolerance 
which can also be attributed to the presence of anti-inflammatory contents such as TGF-β 
and PGE2 (25).  Apoptosis needs to be complemented by a swift removal of the apoptotic 
cell corpse.  The recognition signals ensure the efficient removal of apoptotic cells to 
prevent post-apoptotic necrosis.  If a cell dies by necrosis or if an apoptotic cell fails to be 
cleared and undergoes a secondary kind of necrosis, the intracellular contents are released, 
T cells are activated, and harmful inflammatory responses are produced (6).  
Before an apoptotic cell can be phagocytosed, an activated monocyte needs to 
migrate to the dying cell.  There has been evidence that apoptotic clearance by phagocytes 
is regulated by endogenously produced mediators released by dying cells. Apoptotic cells 
are known to secrete chemotactic factors that stimulate the attraction of monocytic cells 
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and macrophages and facilitate apoptosis (3,6).  The phospholipase A2 (PLA2) family is 
characterized as enzymes that have the ability to catalyze the hydrolysis of the sn2- fatty 
acyl bond position of phospholipids to release free fatty acids and lysophospholipids.  The 
resulting products are the suggested lipid mediators that induce monocyte chemotaxis to 
dying cells (7).  An activated calcium independent phospholipase (iPLA2)  has been shown 
to generate chemotactic factors in a caspase-3 dependent fashion, but other types of 
phospholipases have been shown to generate monocyte chemotaxis to dying cells either 
directly or indirectly also (6).  Our focus will be on secretory phospholipase A2 (sPLA2) 
and its ability to generate chemotactic factors on apoptotic cells.  We will also try to 
identify a possible sPLA2 receptor that aids in trapping  the enzyme on cell surfaces.
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Phospholipases
The phospholipase A2 (PLA2) family catalyzes the hydrolysis of the sn-2 position of 
membrane glycerophospholipids to liberate free fatty acids and lysophospholipids involved 
in the regulation of both physiological and pathological processes.  The common fatty 
acids released by hydrolysis are arachidonic acid (AA) and oleic acid (OA), which are 
important stores of energy.  Arachidonic acid can function as a messenger and precursor of 
various bioactive pro-inflammatory compounds called eicosanoids (including 
prostaglandins, thromboxanes, lipoxins, and leukotrienes) known to mediate inflammation 
and signal transduction.  Lysophospholipids, such as lysophosphatidic acid (LPA) and 
lysophosphatidylcholine (LPC), are important in cell signaling, phospholipid remodeling, 
and membrane perturbation (8, 9). Lysophospholipids are biologically active by 
themselves and are precursors of other bioactive mediators like platelet activating factor 
(PAF).  Phospholipase A2 is involved in many different cellular processes such as 
phospholipid digestion and metabolism, host defense, and signal transduction.   The 
actions of PLA2’s can also be important for down regulating cell signals, as seen with 
PLA2 catalyzed hydrolysis of  platelet activating factor to its inactive lysophospholipid 
form.  PLA2 activity was first studied in pancreatic juice and cobra venom but has recently 
been studied in humans (7).
Presently, 19 different isoforms of PLA2 enzymes have been identified.  The 
various enzymes can be broken down into groups based the location of the enzymes; the 
enzymes are classified as either an extracellular secreted enzyme or an intracellular 
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cytosolic enzyme (10).  Phospholipase A2 can also be divided into three different 
categories based on their calcium dependence and other properties:  cytosolic PLA2 
(cPLA2), secretory PLA2 (sPLA2), and calcium independent PLA2 (iPLA2).  Cytosolic 
PLA2 requires micromolar levels of calcium and is found intracellularly.  sPLA2 requires 
millimolar levels of calcium and is found extracellularly while iPLA2 is completely 
independent of calcium for their activities, but like cPLA, is found intracellularly (11).
Cytosolic PLA2 (cPLA2) enzymes are very important in the initiation of AA 
metabolism and are found to be the most prevalent and the most well studied of the 
cytosolic enzymes (9,10).  Activation of cPLA2 is regulated by micromolar calcium 
binding of cPLA2 to the cell membrane for access to phospholipid substrate (due to a C-2 
domain located in the N-terminus of the enzyme) and phosphorylation by MAP kinases. 
Both are important in the post-receptor signaling transduction. This is the only enzyme 
family that shows a preference for AA over the other fatty acids for the hydrolysis of the 
sn-2 position of phospholipids (9,12).  Cytosolic PLA2’s are also characterized as having a 
catalytic serine that forms an acyl ester intermediate during hydrolysis, which is eventually 
broken down by a water molecule.  According to the Dennis classification, cPLA is also 
known as group IV and has six isoforms that are ubiquitously expressed and lack disulfide 
bonds.  They are known as cPLA2-α, cPLA2-β, and c-PLA2-γ, c-PLA2-δ, c-PLA2-ε, and c-
PLA2-ζ.  Each are characterized as typically having a large molecular weight ranging from 
61-114 kDa but mainly found to be around 85kDa (12).  
Calcium independent PLA2, classified as group VI, is the most recently identified 
category of phospholipases A2 and is known as iPLA2.  These cytosolic enzymes are found 
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in multiple splicing variations and tend to be associated with apoptosis and phospholipid 
remodeling.  Calcium is not required for catalysis in iPLA2 and like cPLA they also do not 
possess disulfide bonds (9).  iPLA2 has a higher molecular weight than cPLA of around 84 
to 88 kDa and the enzyme also possesses a catalytic serine, but its structure is very 
different from the cPLA2 family (1). 
Secreted phospholipase A2 (sPLA2) was originally found in large amounts in 
porcine pancreas.  The enzyme family, consisting of 11 isozymes identified so far, have a 
low molecular weight (14 to 17 kDa), and are calcium requiring (mM) secretory enzymes 
that have been implicated in a number of biological processes such as eicosanoid 
generation, inflammation, and host defense.  The extracellular enzyme was also found to 
be highly disulfide bonded and having a catalytic histidine residue (8).  The seven disulfide 
bonds (and up to two additional unique disulfide bonds) in the sPLA2 family are highly 
conserved, which allows the enzyme to be highly stable (9).  Secreted PLA2’s do not form 
a classical acyl enzyme intermediate characteristic of serine proteases, nor do they display 
any specificity for arachidonic acid in the phospholipids sn-2 position. They use the 
catalytic site histidine, assisted by an aspartate to polarize a bound water molecule, which 
will then attack the carbonyl group. The required calcium ion (needed in millimolar 
concentrations), which is bound in the conserved calcium binding loop, ultimately 
stabilizes the transition state (7). 
The proposed general catalytic cycle for sPLA2 goes as follows:  The enzyme 
partitions from the aqueous phase to the bilayer interface; the enzyme undergoes an 
allosteric activation; catalysis commences; and products are released.  Water soluble 
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enzymes, such as sPLA2, can reversibly interact with membranes and catalyze reactions at 
the interface of an aqueous solution and lipid surface (14).  When sPLA2 is in aqueous 
solution, its calcium containing catalytically active site is buried in a channel lined with 
hydrophobic amino acids. Partition from the aqueous phase to the phospholipid interface is 
critical for catalysis; catalysis in aqueous phase is nonexistent (14,15).  Specifically, for 
group IIA sPLA2, the enzyme binds with highest affinity to bilayers composed of 
negatively charged phospholipids.  This phenomenon is driven in part by electrostatic 
interactions caused  because the rim of the positively charged lysine and arginine residues 
around the entrance to the catalytically active channel is attracted to the negatively charged 
polar groups (anionic phospholipids such as PS and PE found on the outer leaflet during 
early apoptosis) in the lipid membrane (important in interfacial binding) (16)  The cationic 
residues closest to the opening of the active site slot make the most important interactions 
with the membrane.  Binding of the enzyme to the lipid membrane induces a 
conformational change in the phospholipase.  A substrate molecule must leave the 
membrane to travel into the catalytically active site (14, 15).  Binding strength to 
phospholipid heads is increased and a hydrophobic channel containing the active site opens 
allowing the phospholipid molecule to move from the bilayer to inside the channel.  The 
calcium located in the channel binds to the head group of the substrate positioning the ester 
bond to be hydrolyzed next to the catalytic site by a water molecule (15,16).  The 
catalytically active histidine, characteristic of sPLA2, in turn activates a water molecule to 
hydrolyze the ester bond producing free fatty acids and lysophospholipids (17).
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The most abundant phospholipase A2 group found in human tissues is sPLA2 group 
IIA (sPLA2 IIA) (12).  Group IIA PLA2 is known mainly for its role in inflammation 
because it has been shown to be highly expressed in human and rat tissue related to 
immune responses. Group IIA’s signaling properties are generated as a result of the 
biological activity of unesterified fatty acids and lysophopholipids it produces, as well as 
IIA’s ability to perturb cellular membranes by interacting with phospholipids, the ability to 
interact with membrane receptors analogous to those binding other sPLA2’s, and the ability 
to bind heparan sulfate proteoglycans.  Group IIA can release the bioactive compound 
arachidonic acid and produce other eicosanoids via cycloxygenase or lipoxygenase 
enzymes (prostaglandins and leukotrienes) during inflammatory conditions such as 
ateriosclerosis, septic shock, and rheumatoid arthritis (10).  The other reaction products 
generated, lysophosphatidic acid (LPA) or lysophosphatidylcholine (LPC), are also 
biologically active by themselves and are the precursors of other potent bioactive 
mediators such as platelet-activating factor (PAF); all of which are known to be potent 
monocyte chemoattractants (9).  IIA is highly cationic and binds tightly to anionic 
heparanoids such as heparan and heparan sulfate.  Cell surfaces are usually rich in heparan 
sulfate proteoglycans (HSPG) and significant portions of IIA are present in a membrane 
bound form rather than secreted extracellularly when expressed in mammalian cells (9). 
Following binding to HSPG, a number of endocytic routes are available to allow 
internalization of group IIA where the enzyme may be allowed to hydrolyze phospholipids. 
Group IIA has shown great pathophysiological potential because many of its biological 
actions depend on interactions with receptors similar to those involved in the toxic effects 
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of PLA2 found in venoms.  IIA is able to behave as a ligand for a group of receptors that 
are part of the c-type multilectin mannose receptor family.  The receptors, named N-type 
(neuronal) and M-type (muscle), help the enzyme internalize to specific compartments 
within cells where they release AA or other bioactive lipids, which produce biological 
responses (12, 23). Unfortunately, the IIA sPLA2 from the mouse is the only kind of IIA 
found to bind to the M-type receptor suggesting that there are possibly other receptors 
involved in binding the human form of IIA sPLA2.
Recent studies have shown that apoptotic cells induce chemotactic factors in a 
caspase-3 dependent function via activation of the intracellularly located phospholipase A2, 
iPLA2.  The activation of iPLA2 was required for the release of the chemotactic factor 
lysophosphatidylcholine which was found to be important in the migration of monocytes to 
apoptotic cells.  Secretory phospholipase A2 is also able to generate the production of LPC 
from the hydrolysis of anionic phosphatidylcholine located on the membrane of cells that 
have undergone apoptosis (6).  Boilard suggested that the highly cationic group IIA sPLA2 
binds with high affinity to cells undergoing apoptosis because of an increase in exposed 
anionic phospholipids on the outer leaflet of the phospholipid membrane and perturbed 
membrane asymmetry (18).  Even though once cells have become apoptotic, they have an 
increased attraction to the action of group IIA, the membrane asymmetry of apoptotic cells 
may not be good enough to allow an association between IIA and the now majority anionic 
phospholipids membrane.  In early apoptotic cells, IIA has also been found to interact with 
anionic heparan sulfate proteoglycans and other specific cell surface receptors such as 
vimentin through receptor ligand interactions (23).  Both of these mechanisms of apoptotic 
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cell interaction with IIA sPLA2 are possible explanations of how IIA mediated hydrolysis 
of membrane phospholipids occurs resulting in the production of fatty acids and 
lysophospholipids that are capable of producing chemoattractant signals for phagocytic 
uptake.  
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Hypothesis
Based on previous reports by Boilard and studies done in our lab, sPLA2 binds 
preferentially to apoptotic cells via interaction with an unknown receptor.  Once sPLA2 
binds to the apoptotic cell and exerts a biological response, monocytes are able to migrate 
to the dying cell.  We hypothesize that the exposure of heparan sulfate proteoglycans on 
apoptotic cells traps a pool of catalytically active sPLA2 that produces chemoattractant 
lipids that recruit macrophages to phagocytose the apoptotic cells. 
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Materials and Methods
Cell culture:  Jurkat cells were cultured in modified RPMI-1640 medium (Cellgro), 
supplemented with 10% heat inactivated fetal calf serum, 2mM L-glutamine, 100ug/mL 
penicillin and 100ug/mL streptomycin, at 7.5% CO2, 100% humidity and 37ºC.  THP-1 
monocytes were cultured in modified RPMI-1640 medium (Cellgro), supplemented with 
10% heat inactivated fetal calf serum, 2mM L-glutamine, 100ug/mL penicillin and 100ug/
mL streptomycin, at 7.5% CO2, 100% humidity and 37ºC.  Human Embryonic Kidney cells 
(HEKs) were maintained in modified DMEM (Cellgro) supplemented with 10% heat 
inactivated fetal calf serum, 2mM L-glutamine, 100ug/mL penicillin and 100ug/mL 
streptomycin, at 5% CO2, 100% humidity and 37ºC.  Cell viability was determined by 
Trypan Blue dye exclusion with a hemacytometer.
Induction of Apoptosis via antiFas:  Fas-mediated apoptosis was induced by adding 
20ng/mL CD95 (AntiFas, BD Pharmingen) to 1x106 cultured Jurkat cells/mL.  Cells were 
then incubated in 7.5% CO2, 100% humidity at 37ºC for varying time points (2, 4, 6, 8, 10, 
12, 14, 16, 24 hours).  Apoptosis was monitored through annexin-V binding and PI 
staining (Vybrant apoptosis assay kit, Molecular Probes) followed by flow cytometric 
analysis.
Induction of apoptosis via dihydrosphingosine:  Apoptosis was induced by adding 10uM 
DHS (obtained from Dr. Sarah Spiegel) to 1x106 cultured Jurkat cells/mL.  Cells were then 
incubated in 7.5% CO2, 100% humidity at 37ºC for varying time points (0, 2, 3, 4 hours). 
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Apoptosis was monitored through annexin-V binding and PI staining (Vybrant apoptosis 
assay kit, Molecular Probes) followed by flow cytometric analysis.
Flow cytometric analysis of cell viability:  Both treatment and control cells were 
harvested and pelleted. After washing with PBS, the cells were re-suspended to a volume 
of 1x106/mL 1X Annexin Binding Buffer (Vybrant apoptosis assay kit, Molecular Probes). 
Solutions of 100ug/mL Propidium Iodide and FITC-Annexin V were prepared and each 
was added to 100uL of the cells in 1X ABB (1uL and 5uL, respectively).  The cells were 
then incubated in the dark, at room temperature, for 15 minutes. Four-hundred microliters 
(400uL) 1X ABB was added to the cells, and the final volumes were then stored on ice to 
be later analyzed by a BD FACSCAN flow cytometer.  Using CellQuest Pro software, 
gates were set using control cells as the basis for determining normal, viable cells.  Dot 
plots produced showed the forward angle light scatter (FSC), which relates to the cell 
diameter, versus the side angle light scatter, which relates the density of the inner cellular 
structures.  Annexin V-FITC staining helped to discriminate between apoptotic and non-
apoptotic cells.  Propidium iodide is a vital dye exclusion test which collects information 
about the membrane integrity. Both were used to set quadrants to distinguish between non-
apoptotic, early apoptotic, late apoptotic, and necrotic cells. Statistical analysis of the 
different categories was determined using WinMDI.
Group IIa sPLA2 Plasmid Transfection:  Mammalian expression vector encoding human 
group IIa sPLA2 was obtained from Dr. Mike Gelb (University of Washington).  Cultured 
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human embryonic kidney cells (500,000 cells/well) were transiently transfected via the 
FuGENE 6 Transfection protocol (Roche) with the 1ug of the IIa plasmid to over express 
the enzyme.  After 36 hours of incubation at 5% CO2, 100% humidity at 37ºC, harvested 
cultured supernatant was used as source of group IIa sPLA2.
Activity Assay:  The measurement of enzymatic activity by group IIa was done utilizing 
[3H] Oleic acid labeled E. coli cells as a substrate. Fifty microliters of culture supernatant 
or acid extracted enzyme was incubated with ~65,000 cpm of E. coli cells in assay buffer 
(25mM Tris-base, pH 9.0, 10mM calcium chloride, 5mg/mL fatty acid free bovine serum 
albumin) along with 100 mg/mL FAF-BSA, and 1M CaCl2.  Molecular Biology Grade 
water was added to the enzyme/substrate mixture for a final volume of 500uL which was 
incubated for 20 minutes at 37ºC.  The addition of 250uL 2N HCL and 250 uL 20 mg/mL 
FAF-BSA stopped the reaction and extracted free fatty acids, respectively.  The volume 
was incubated on ice for 20 minutes, then centrifuged at 7500 x g and 400uL of 
supernatant was used for scintillation counting.  The percent hydrolysis was assessed based 
on counting the amount of released radiolabeled oleic acid  (percent of input counts 
released into supernatants).
Acid Extraction of Group IIa Secreted PLA2:  Acid extraction of IIa sPLA2 denatures all 
proteins but the IIa enzyme while also keeping the enzyme stable.  After incubation with 
DHS, 2x106 cultured Jurkat cells were re-suspended in 1mL PBS.  Twenty-five microliters 
of group IIa sPLA2 (culture supernatant from IIa Plasmid Transfection) was added to the 
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Jurkat cells and incubated on ice for 30 minutes (control cells contained no enzyme). 
Treatment and control samples were then centrifuged for 20 minutes at 5000 x g. The 
supernatant was discarded and the cell pellet was washed in 3mL PBS.  To inactivate the 
IIa enzyme, the pellet was re-suspended in 750uL of 0.36N sulfuric acid and left overnight 
at 4ºC. The next day, the cells were centrifuged for 20 minutes and the supernatant was 
saved and stored at 4ºC.  The supernatant was used as an enzyme source and used in the 
activity assay.
Production of Cell Chemoattractant:  Early apoptotic and control cells were re-
suspended in PBS supplemented with CaCl2 at a concentration of 106 cells/mL. Twenty-
five microliters of group IIa s PLA2 was added to the concentration of cells and incubated 
on ice for 30 minutes.  The cells were then incubated in a warm water bath at 37ºC for 20 
minutes with the shaker at moderate speed. The cells were centrifuged at 7500 x g for 5 
minutes and the supernatants were used as chemoattractants for the chemotaxis assay.
Chemotaxis Assay:  Transwell plates (8um pore, Fisher) were used for the chemotaxis 
assay. Both the upper and lower chambers of the wells were pre-incubated with 2% FCS 
for 1 hour. After the removal of the 2% FCS medium, 300uL of chemoattractant along 
with 300 uL of 2% RPMI was placed in the lower chamber of the transwell.  One-hundred 
microliters (100uL) of THP-1 monocytes, which were previously cultured to 1x106/mL, 
were added to the upper chamber of the transwell.  The wells were incubated for 2 hours at 
37ºC.  After 2 hours the contents of each chamber were transferred to separate Falcon 
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tubes for analysis of migration by the Beckman Coulter Cytomics FC 500 Series  flow 
cytometer.  Percent chemotaxis was calculated as percent of total cells migrated to the 
lower chamber.
Para-bromophenacylbromide (BPB) Inactivation of IIa sPLA2:   Three milliliters 
(3mL) sPLA2 enzyme was incubated with 200mM BPB (in PBS with EtOH as a co-
solvent) on ice for 30 minutes.  For removal of residual BPB, both the treatment and 
control samples were dialyzed against PBS for 16 hours at 4ºC using 3.5K dialysis tubing. 
The dialyzed enzymes were then tested for catalytic activity using the activity assay.  The 
dialyzed enzymes were also used as a source of IIa sPLA2 in a modified cell 
chemoattractant production assay.
Blockage of Heparan Sulfate Proteoglycan binding sites on sPLA2 via Heparin: 
Heparin was used in solution with sPLA2 to see if sPLA2 was able to bind to heparan 
sulfate proteoglycans on the surface of Jurkat cells and exert catalytic activity.  Two 
million Jurkat cells were cultured and re-suspended in one milliliter of different heparin 
concentrations (500ug, 250ug, or 50ug/mL PBS).  The acid extraction assay was 
performed and catalytic activity was assessed via the activity assay.  The percent 
hydrolysis was assessed (percent of input counts released into supernatants).
Heparinase III activity assay:  Jurkat cells were incubated in 50mU/mL heparinase III for 
5 hours at 37ºC ( 2x106 Jurkat cells/mL heparinase).  The cells were then re-suspended in 
17
1mL PBS.  The acid extraction assay was performed and catalytic activity was assessed via 
the activity assay.  The percent hydrolysis was assessed (percent of input counts released 
into supernatants).
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Statistical Analysis:  Data shown are mean and standard deviation of multiple 
experiments done in triplicate or other replicate noted.  Statistical significance was 
determined by using the student’s t-test with p < 0.05.
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Results
Figures 1 and 2. 
Forward scatter by side scatter analysis along with propidium iodide and annexin v-
FITC staining shows Jurkat cells are viable and mainly non-apoptotic.  One million 
Jurkat cells were grown under cell culture conditions without the presence of 
dihydrosphingosine.  Cells were stained with propidium iodide and annexin v-FITC and 
analyzed with a flow cytometer.  Forward scatter vs Side Scatter:  Dead cells are located in 
R0 and live cells are in R1.  UL (necrotic): PI (+), AnnexinV-FITC (-); UR (late 
apoptotic): PI (+), AnnexinV-FITC (+), LL (live): PI (-), Annexin V-FITC (-);  LR (early 
apoptotic) : PI (-), Annexin V-FITC (+).   Experiment was repeated in triplicate, with this 
being the single representative experiment.
 
0 hours FSC/SSC 0 hours PI/Annexin-V FITC
      
Figure 1 Figure 2
QUAD % TOTAL % GATED
UL 1.03 1.03
UR 7.4 7.4
LL 88.94 88.94
LR 2.63 2.63
Region % total % gated
R1 90.35 90.35
R0 9.65 9.65
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Figure 3 and 4. 
Incubation of Jurkat cells with dihydrosphingosine for 2 hours shows initial 
progression into early apoptosis.  One million Jurkat cells were incubated for two hours 
in the presence of DHS.  The Jurkat cells were stained with propidium iodide and annexin 
v-FITC and analyzed with a flow cytometer.  Forward scatter by side scatter dot plot 
shows the population of live cells in R1 and dead cells in R0.  Annexin-V/FITC staining 
shows cell progression into apoptosis.  UL (necrotic): PI (+), AnnexinV-FITC (-); UR (late 
apoptotic): PI (+), AnnexinV-FITC (+), LL (live): PI (-), Annexin V-FITC (-);  LR (early 
apoptotic) : PI (-), Annexin V-FITC (+).   Experiment was repeated in triplicate, with this 
being the single representative experiment. 
2 hours SSC/FSC 2 Hours PI/Annexin-V FITC
Figure 3       Figure 4
QUAD
% 
TOTAL % GATED
UL 0.71 0.71
UR 18.15 18.15
LL 63.51 63.51
LR 17.63 17.63
Region % total % gated
R1 80.28 80.28
R0 19.72 19.72
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Figure 5 and 6. 
Effect of three hour incubation of Jurkat cells with dihydrosphingosine via foward 
scatter by side scatter analysis and propidium iodide and annexin –v/FITC staining 
shows a decrease in the population of viable cells.  One million Jurkat cells were 
incubated for three hours in the presence of DHS.  The Jurkat cells were stained with 
propidium iodide and annexin v-FITC and analyzed for apoptotic progression with a flow 
cytometer.  Forward scatter by side scatter dot plot shows the population of live cells in R1 
and dead cells in R0.  UL (necrotic): PI (+), AnnexinV-FITC (-); UR (late apoptotic): PI 
(+), AnnexinV-FITC (+), LL (live): PI (-), Annexin V-FITC (-);  LR (early apoptotic) : PI 
(-), Annexin V-FITC (+).   Experiment was repeated in triplicate, with this being the single 
representative experiment.
3 Hours SSC/FSC 3 Hours PI/Annexin-V FITC
Figure 5      Figure 6
QUAD % TOTAL % GATED
UL 0.09 0.09
UR 44.57 44.57
LL 8.62 8.62
LR 46.72 46.72
Region % total % gated
R1 53.86 53.86
R0 46.14 46.14
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Figure 7 and 8. 
Jurkat cells incubated with dihydrosphingosine for four hours and analyzed with 
forward scatter by side scatter flow cytometry show equal populations of viable and 
dead cells.  Annexin-V/FITC and propidium iodide staining show a majority of cells 
in early or late apoptosis.  One million Jurkat cells were incubated for four hours in the 
presence or absence of DHS.  The Jurkat cells were stained with propidium iodide and 
annexin v-FITC and analyzed with a flow cytometer. UL (necrotic): PI (+), AnnexinV-
FITC (-); UR (late apoptotic): PI (+), AnnexinV-FITC (+), LL (live): PI (-), Annexin V-
FITC (-);  LR (early apoptotic) : PI (-), Annexin V-FITC (+).  Forward scatter by side 
scatter dot plot shows the population of live cells in R1 and dead cells in R0.   Experiment 
was repeated in triplicate, with this being the single representative experiment. 
4 Hours SSC/FSC 4 Hours PI/Annexin V FITC
Figure 7      Figure 8
 
QUAD % TOTAL % GATED
UL 0.35 0.35
UR 48.04 48.04
LL 1.61 1.61
LR 50 50
Region % total % gated
R1 50.01 50.01
R0 49.99 49.99
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Flow cytometric forward by side scatter analysis shows live and dead cell populations: 
According to Boilard, early apoptotic cells are preferentially bound by sPLA2, possibly 
because of the exposure of PS and vimentin (23).  Jurkat cells were made early apoptotic 
via DHS because it has the ability to quickly induce cell apoptosis without increasing 
necrotic cell death (20).  For our experiment we wanted to generate a population of early 
apoptotic cells. The gated region of the plot refers to the population of cells that were 
analyzed as being live, early apoptotic, late apoptotic, or necrotic (Figures 2, 4, 6, and 8). 
Dot plots produced show the forward angle light scatter (FSC), which assesses the cell 
diameter, versus the side angle light scatter (SSC), which relates  to the density of the inner 
cellular structures (Figures 1, 3, 5, and 7) (26). The R1 region includes vital cells while the 
R0 (non-gated) region is necrotic/apoptotic cells. As apoptosis occurs, the cell shrinks, and 
the forward angle light scatter population decreases.  This correlates with an increase in 
side scatter, which is an increase cytoplasmic granularity. When apoptotic analysis is 
applied to flow cytometric gated regions, cells displaying a progression in apoptosis 
exhibit a decrease in the R1 population and an increase in the R0 population (26). 
For the shown dot plots, as cells are incubated with DHS for longer time points, the 
percentage of cells in the gated regions decreases for region 1 and increases for region 0. 
Jurkat cells incubated with no DHS show a 90.3% viability.  Jurkat cells incubated with 
DHS for 2, 3, and 4 hours show a decrease in cell viability as shown by 80.3%, 53.9%, 
50% viability, respectively.  The decrease in cell viability and the decrease in the 
population of cells in R1 suggest cells are shrinking in size and possibly going through 
apoptosis. Jurkat cells located in the non gated region are classified as necrotic or apoptotic 
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cells.  An increase in the incubation time of cells applied with DHS show an increase in the 
population of apoptotic or necrotic cells.  Control Jurkat cells containing no DHS show 
9.7% of the cells being in the R0 region.  Jurkat cells incubated with DHS for 2, 3, and 4 
hours show an increase in the side scatter population region producing 19.7%, 46.1%, and 
50% of cells in apoptosis or necrosis respectively.  By the fourth hour of incubation in 
DHS, there were approximately equal populations of cells in both regions.  The overall 
increase in side scatter percentages and decrease in forward scatter percentages suggests 
the Jurkat cells are dying.  
25
Use of Propidium Iodide and Annexin V- FITC after Jurkat cell incubation with 
dihydrosphingosine differentiates live, early apoptotic, late apoptotic, and necrotic cells  
via flow cytometric analysis:  Jurkat cells were stained with both propidum iodide (PI) and 
annexin v-FITC (AVF) after incubation with or without DHS.  Propidium iodide is 
generally membrane impermeable and stains DNA in leaky cells. It is ultimately used as a 
vital dye exclusion test between viable and dead cells, similar to trypan blue (27). 
Annexin-FITC staining is used as a test to determine apoptotic progression; distinguishing 
between apoptotic and non- apoptotic cells.  Annexin-FITC is found to bind to anionic 
phospholipids such as phosphatidylserine which flips to the outer leaflet of cells during 
early apoptosis (27).
Quadrants were set for the dot plots comparing propidium iodide staining to 
annexin V-FITC staining (Figures 2, 4, 6, and 8).  The lower left (LL) quadrant designates 
live, viable cells, the lower right (LR) quadrant applies to early apoptotic cells, the upper 
right (UR) quadrant applies to late apoptotic cells, and the upper left (UL) quadrant applies 
to necrotic cells.  Jurkat cells in the LL quadrant are both PI and AVF negative, Jurkat cells 
found in the LR quadrant are PI negative and AVF positive, Jurkat cells found in the UR 
quadrant are both PI and AVF positive, and Jurkat cells found in the UL quadrant are PI 
positive and AVF negative.  Both the lower right and lower left quadrants are viable cells 
which relate to the R1 region while the upper right and upper left quadrants are necrotic 
and apoptotic cells which relate to the R0 region.  Since we were interested in the overall 
generation of early apoptotic Jurkat cells, the lower right quadrant will be the most 
important quadrant in this study.  We will be comparing control cells to cells incubated in 
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DHS for four hours because the four hour time point analysis of annexin-V versus PI has 
the largest ratio of early apoptotic cell population compared to control cell population 
(Figures 1 and 2 versus Figures 7 and 8).  The total population of cells were analyzed (R1 
and R0). The four hour incubation alone also has the smallest ratio of early apoptotic 
versus late apoptotic cells (1 fold).  Analysis of the lower left quadrant for each time point 
shows a negative relationship between the incubation time of cells with DHS and the 
reduction of live cells.  There is a fifty-five fold decrease in live cells located in the LL 
quadrant when control cells are compared to cells incubated for 4 hours in DHS (88.9% to 
1.6%).  The lower right quadrant, which contains the population of cells we are most 
interested in, shows a nineteen fold increase in the population of early apoptotic cells 
(2.6% to 50%).  The population of late apoptotic cells in the upper right quadrant exhibit a 
6.5 fold increase from 7.4% in control cells to 48% in cells incubated with DHS for four 
hours.  The Jurkat population located in the upper left quadrant, which designates necrotic 
cells, shows a 3 fold decrease (1% to 0.35%).  This is probably attributed to cells which 
were dead before the DHS was applied, as seen by similarly low necrotic percentages in all 
other time points.  Overall there is a negative correlation between cell viability and DHS 
incubation time.  When the DHS incubation time increases from two hours (63.5% viable 
cells in LL), 3 hours (8.6% in LL), and 4 hours (1.6% in LL), there is an increase in the 
population of early apoptotic cells from 2, 3, and 4 hours (17.6%, 46.7%, 50%, 
respectively in the LR quadrant).  Ultimately, as Jurkat cells are incubated for longer times 
in DHS, cell viability decreases.  
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Figure 9.
Cultured supernatant from sPLA2 IIA transfected HEK’s used as a source of group 
IIa sPLA2 are shown to exhibit enzymatic activity.  Human embryonic kidney cells were 
transiently transfected with group IIA sPLA2 vector plasmids or control in DMEM as 
described in the material and methods.  Cultured supernatants were harvested after 36 
hours and enzymatic activity was calculated based on percent hydrolysis of released 
radiolabeled oleic acid.  Results are a single representative experiment done in triplicate.
Human embryonic kidney cells transfected with IIA vector plasmid produces culture 
supernatant that has phospholipase activity:  To generate a source of IIA sPLA2, a cultured 
supernatant produced from HEK transfection was used in our experiments.  Human 
embryonic kidney cells were transiently transfected with a mammalian expression vector 
encoding human group IIa sPLA2 and enzymatic activity of the phospholipase was found 
to have 26.1% hydrolysis of the substrate.  The control, which contains an enzyme source 
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that was made by transfected  HEK’s in the absence of group IIa sPLA2 plasmids, shows a 
0.7% hydrolysis of the substrate.  The blank contains no enzyme, and exhibits a 0.003% 
non enzymatic hydrolysis of the substrate.  There is a 37 fold increase in hydrolysis when 
the control is compared to the group IIa enzyme.
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Figure 10.
Catalytically active group IIa sPLA2 enzyme binds control and DHS treated-early 
apoptotic cells equally with no specific preference.  Jurkat cells incubated in the 
presence of DHS or absence of DHS were harvested after four hours.  Different volumes of 
group IIa sPLA2 was added exogenously to the Jurkat cells.  An acid extraction was 
performed on the cells as explained in material and methods, and the percent hydrolysis 
was assessed.  Data shown is from four compiled experiments done in triplicate.
Catalytically active group IIa sPLA2 enzyme binds control and DHS treated-early 
apoptotic cells equally:  As previously mentioned, sPLA2 has a preference for anionic 
phospholipids such as PS and PE, which are seen on cell surfaces during early apoptosis 
(18).  Live and apoptotic cells have a difference in the kinds of phospholipids and receptors 
available on their cell surfaces.  Comparison of control cells and cells treated with DHS in 
the PI/AVF analysis show a 19 fold increase in the population of early apoptotic cells. 
According to previous findings, early apoptotic cells bind to sPLA2 with a greater 
preference than non-apoptotic cells because the sPLA2 is attracted to the anionic 
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phospholipids which flip to the outer membrane during apoptotic progression.  We wanted 
to see if there was a difference in the ability of IIA to hydrolyze exposed phospholipids on 
live or early apoptotic cells.  The results in figure ten show that regardless of the volume of 
sPLA2 incubated with Jurkat cells, there is no statistically significant difference of enzyme 
activity between the group IIa sPLA2 cell bound extracts from either the control group or 
the early apoptotic population of cells.  Apoptotic cells incubated with IIA supernatant 
produced extracts that had statistically significant differences in the ability to hydrolyze 
substrate in a dose dependent manner.  However, extract received from live cells incubated 
with IIA had no statistically significant differences in the ability to hydrolyze substrate in 
correlation to the increased sPLA2 volumes.  The only extracts (for both apoptotic and non-
apoptotic cells) that proved to be statistically relevant when assessing the percent 
hydrolysis were the extracts produced from cells that had been incubated with one-hundred 
microliters of sPLA2.  Though the extracts produced from cells incubated with 100 
microliters sPLA2 demonstrated a hydrolysis percentage that was statistically different 
when compared to the other samples, there was still no difference in the ability of sPLA2 
to hydrolyze phospholipids on control or early apoptotic cells.  There was a dose 
dependent increase in enzymatic activity as the amount of exogenous sPLA2 added to cells 
increased, but there was no statistically significant difference in enzymatic activity 
between control or early apoptotic cell extracts.  Similar hydrolysis activity suggests that 
sPLA2 binds non apoptotic and control cells with same specificity. Based on previous 
reports from Boilard, we expected there to be a significant difference between the 
interaction of sPLA2 on apoptotic and non apoptotic cell populations, with the early 
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apoptotic cells exhibiting higher enzymatic activity, but our results proved otherwise.
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Figure 11.
Pool of catalytically active group IIa sPLA2 “trapped” on the surface of Jurkat cells 
generates chemoattractants which cause THP-1 monocyte chemotaxis directly or 
indirectly.  sPLA2 culture supernatant was exogenously added to live Jurkat cells and a 
chemoattractant was produced using the chemoattractant protocol as stated in materials and 
methods.  Twenty-five microliters of sPLA2 culture supernatant was incubated with Jurkat 
cells and the resulting chemoattractant/extract produced was placed in the bottom chamber 
of a transwell along with 2% RPMI 1640 medium until the final volume reached 600uL. 
The negative control was generated from Jurkat cells that were incubated with no sPLA2. 
One hundred THP-1 monocytes were added to the top chamber of the transwell and after 2 
hours the percent of THP-1 monocytes that migrated from the top chamber to the bottom 
chamber was calculated from three replicates. Data shown is from a single representative 
experiment.
Catalytically active sPLA2 IIA trapped on Jurkat cell surfaces produces a chemoattractant  
which causes THP-1 monocytes to migrate in a dose dependent manner
:  The products generated from the hydrolysis of phospholipids by sPLA2 are fatty acids 
and lysophospholipids.  Examples of these products include LPC and AA which are both 
known chemotactic mediators (9).  Since we previously noted that there was no difference 
  *
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in the ability of IIA to bind live or non-apoptotic cells, this experiment was done to see if 
IIA bound to live Jurkat cells had the ability to generate chemoattractants that attracted 
THP-1 monocytes.  Transmigration was performed by adding THP-1 monocytes to the 
upper chamber of a transwell and different amounts of chemoattractant in the lower 
chamber of the transwell.  The migration of THP-1 monocytes from the upper chamber to 
the lower chamber was calculated as percent of THP-1 monocytes transmigrated.  The 
assay was found to have a positive dose dependent increase correlating to the migration of 
THP-1 monocytes; as the volume of chemoattractant increased in the bottom chamber, the 
percentage of migrated monocytes increased.  The percentage of monocyte chemotaxis in 
the negative control showed no statistically significant differences as the amount of extract 
in the bottom transwell changed.  There was a dose dependent increase in the amount of 
THP-1 migration, but as stated previously there was no statistically significant difference 
when comparing the extracts (excluding 0 microliters).   For the samples containing 
chemoattractant produced from incubation of Jurkat cells with sPLA2, the control had 1.6% 
of the THP-1 monocytes migrate from the upper chamber to the lower chamber.  The 
treatment sample containing 100uL chemoattractant in the lower chamber had a 6.3% 
migration, but was not statistically significantly different from the control.  The 200uL 
treatment had a 14.6% migration, and the 300uL treatment had a 37.8% migration of 
monocytes.  The treatment containing 300uL chemoattractant had the largest fold 
difference (24 fold) in comparison the control and was ultimately used as the basis for the 
amount of chemoattractant used in all other assays involving chemotaxis.
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Figure 12.
Group IIa sPLA2 generates soluble bioactive molecules which induce THP-1 
monocyte chemotaxis directly or indirectly in both anti-Fas induced apoptotic cells 
and non apoptotic cells.  Control and antifas-treated Jurkat cells were harvested at 12hrs 
and processed to obtain cell supernatants for chemotaxis as described in methods. Six 
hundred microliters of 10 nM MCP-1 prepared in 2% FCS RPMI 1640 medium, and 100 
uL of possible chemoattractant for samples IIa only, F-,F+, and C+ was added to 500 uL of 
2% FCS RPMI 1640 medium and placed in lower chamber of  transwells. All samples 
received 100,000 THP-1 monocytes in upper chamber. (+)= with IIa, (-)= without IIa.
Group IIa sPLA2 generates soluble bioactive molecules which induce THP-1 monocyte  
chemotaxis directly or indirectly :  Since sPLA2 added to non-apoptotic cells was found to 
generate a chemoattractant, we wanted to see if there was a difference in the 
chemoattractants produced from non-apoptotic versus apoptotic cells and their ability to 
induce monocyte chemotaxis.  We did this experiment using anti-Fas and not DHS because 
we were trying to confirm and extend Boilard’s work (18, 23).  Monocyte Chemotactic 
Protein-1 is a potent β-chemokine that recruits monocytes and promotes cell adhesion and 
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transmigration across an endothelial layer into tissue via a PKC signaling pathway.  The 
MCP-1 was used as a positive control to compare potency of the group IIa sPLA2 products 
as chemoattractants.  Supernatants of both the control and anti-fas cells treated with IIa 
sPLA2 contained a chemotactic factor which was equally as effective as MCP-1 in 
recruiting THP-1 monocytes.  On the other hand, supernatant of anti-fas treated cells 
without group IIa sPLA2 treatment minimally affected transmigration of monocytes and 
was about 50% less compared to MCP-1.  Also group IIa sPLA2 alone had no affect on 
chemotaxis.  These data suggest that sPLA2 acts on Jurkat cells to generate 
chemoattractants (28). 
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Figure 13.
BPB inactivation of group IIa sPLA2.  Dead enzyme was generated to see if catalytic 
activity as required for chemotaxis.  sPLA2 culture supernatant was incubated with 200mM 
para-bromophenacylbromide for 30 minutes, then dialyzed against PBS using 3.5K 
dialysis tubing.  The inhibited enzyme was tested for catalytic activity using the activity 
assay as described in methods.  Data shown is single representative experiment, done in 
triplicate.
 
BPB is able to inhibit the catalytic activity of IIA sPLA2:  Para-bromophenacylbromide is 
an irreversible inhibitor of sPLA2 that does not inhibit other forms of PLA2.   A source of 
catalytically inactive enzyme needed to be made to see if enzyme activity was required for 
chemotaxis.  Analysis of catalytic activity shows that BPB inhibits sPLA2.  Catalytic 
activity is shown to cease when the enzyme is treated with BPB.  The BPB treated enzyme 
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has a percent hydrolysis below control which means that the enzyme had no affect on the 
hydrolysis of glycerophospholipids located in the radiolabeled oleic acid substrate.  The IIa 
enzyme, which was treated with a vehicle (PBS), still showed high catalytic activity by 
hydrolyzing 13.1% of the substrate.
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Figure 14.
Monocyte chemotaxis is independent of sPLA2 activity.  Two million live Jurkat cells 
were suspended in 1 milliliter of PBS and incubated with 60 uL BPB treated enzyme, or 
vehicle treated enzyme for thirty minutes on ice. Another sample, containing no Jurkat 
cells, was also incubated with BPB treated enzyme for thirty minutes on ice.  The 
chemoattractant protocol was followed with the resulting chemoattractants used in the 
chemotaxis assay.  The average fold change was calculated using the fold changes from 
each experiment.  The fold changes were calculated by getting the ratio of the percentage 
of THP-1 monocytes migrated from the upper chamber to the lower chamber in treated 
samples (vehicle, bpb, no Jurkat cells) versus the control samples which contained no 
chemoattractant. Data shown is average of six experiments done in triplicate.
Catalytically active sPLA2 is not required for monocyte chemotaxis:  sPLA2 IIA produces 
possible chemoattractants via catalytic hydrolysis of anionic phospholipids.  If catalytic 
activity of the enzyme is inhibited, we hypothesize an abolishment of monocyte 
chemotaxis.  The effect of catalytic activity on THP-1 monocyte migration was tested. 
Based on the results provided, THP-1 monocytes are able to migrate regardless of enzyme 
activity.  There was a 2.64 fold average increase in the amount of THP-1 monocytes that 
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migrated when using the enzyme dialyzed against the vehicle as a chemoattractant, in 
comparison to the control.  THP-1 monocytes that migrated using BPB inactivated enzyme 
had a 2.45 fold average increase in comparison to the control. Statistically, there is no 
significant difference between the two treatment samples.  When there are no cells present 
during the chemoattractant production, there is a 0.40 fold difference when compared 
against the control.  sPLA2 activity is  not required for optimal chemotaxis; the whole 
response is independent of catalytic activity. This observation suggests that the enzyme 
may stimulate Jurkat cells to produce chemoattractants through binding to heparan sulfate 
proteoglycans, the  M-type receptor, or other cell surface receptors. Also, the source of 
bioactive lipids, which produce the chemoattractants, could be produced intracellularly by 
other PLA2’s such as iPLA2 or cPLA2.
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Figure 15.
Addition of heparinase drastically prevents sPLA2 binding to Jurkat cell surfaces. 
Two million Jurkat cells were incubated in the presence or absence of 50uM heparinase for 
5 hours.  Group IIA sPLA2 was exogenously added to the cells after they were washed and 
re-suspended in PBS.  The acid extraction protocol was followed and percent hydrolysis 
was calculated with from the average of four different experiments done in quadruplicate.
 
Addition of heparinase III prevents sPLA2 IIA substrate hydrolysis:  Heparinase cleaves 
cell surface heparan sulfate proteoglycan chains. sPLA2 is thought to bind to these heparan 
sulfate proteoglycan chains in a receptor ligand interaction.  If the HSPG are able to trap a 
pool of catalytically active sPLA2, hydrolysis of cell surface phospholipids may occur. 
Once sPLA2 binds to the HSPG receptors, it is in a position close enough to cell surface 
glycerophospholipids.  The new position may ultimately allow for hydrolysis of the cell 
surface glycerophospholipids to produce fatty acids and lysophospholipids.  This 
experiement was done in order to identify a possible enzyme receptor.  Jurkat cells that 
were not incubated in heparinase show a 6.63% hydrolysis of the substrate whereas cells 
that were incubated in heparinase have a 0.45% of hydrolysis.  The 15 fold decrease in 
group IIA’s ability to hydrolyze cell surface phospholipids when heparinase is present, 
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suggests heparan sulfate proteoglycans act as a receptor to trap the enzyme on the cell 
surface.  When these “receptors” are cleaved, sPLA2 has no receptor to bind to, which 
means it can no longer access the phospholipids located on the cell surface and hydrolyze 
them.
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Discussion
We hypothesized that group IIA secretory phospholipase A2 preferentially binds to heparan 
sulfate proteoglycan chains exposed on early apoptotic cells ultimately generating lipid 
chemoattractants that mediate THP-1 monocyte chemotaxis.  The guideline for our study 
was based on previous studies done by Boilard and his colleagues.  They examined the 
interaction between group IIA sPLA2 and early apoptotic induced via anti-Fas.  Apoptosis 
is characterized by dramatic disruption to the cellular structure that contributes to 
programmed cell death and also prepare cells for removal by phagocytes for prevention of 
unwanted immune responses (2).  Based on previous studies done by Boilard and his 
colleagues, T-cells were induced to undergo apoptosis via anti-Fas (18). Antigen driven T-
cell apoptosis involves Fas, the cognate cell surface receptor that interacts with the death 
cytokine Fas ligand to assemble caspase-activating protein complexes which ultimately 
lead to programmed cell death (19).  Our studies induced early apoptosis via D, L-threo-
dihydrosphingosine (DHS).  DHS is a sphingosine kinase inhibitor which induces 
apoptosis without significantly increasing necrotic cell death.  Apoptotic cells have been 
found to induce the expression of sphingosine kinase 1 to release sphingosine-1-phosphate 
which acts as a recognition and uptake signal for cells to phagocytose (20).  Jurkat cells 
incubated with 10uM/mL DHS for 0, 2, 3, and 4 hours showed a gradual progression into 
apoptosis via analysis of forward scatter/side scatter dot plots (Figures 1, 3, 5, and 7). 
Forward angle light scatter relates to the cell diameter while side angle light scatter relates 
to the density of inner cellular structures.  As apoptosis occurs, the cell shrinks, and the 
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forward angle light scatter population decreases. This correlates with an increase in side 
scatter population which is an increase in the density of cellular structures.  To further 
verify that the Jurkat cells were undergoing apoptosis they were stained with both 
propidium iodide and annexin-V FITC and defined as “live”, early apoptotic, late 
apoptotic, or necrotic.  Annexin binds negatively charged phospholipids in a calcium 
dependent manner while propidium iodide, which is generally membrane impermeable, 
stains DNA in leaky cells (3).  There was a nineteen fold increase in the ratio of early 
apoptotic cells which had previously been incubated in DHS for four hours compared to 
Jurkat cells incubated in vehicle for the same amount of time (Figures 7 and 8).  Human 
embryonic kidney cells transfected with group IIA sPLA2 vector plasmids were found to 
show significant catalytic activity (Figure 9).  Different volumes of IIA sPLA2 culture 
supernatant produced from the transfected HEK cells was exogenously added to treated 
and control cells.  Contrary to previously published studies by Boilard and his collagues, 
early apoptotic cells did not preferentially bind sPLA2 IIA when compared to control cells. 
Statistically speaking there was no significant difference between the two groups (Figure 
10).  This was surprising because in most mammalian cells, anionic phospholipids 
segregate preferentially in the inner leaflet of the plasma membrane bilayer, and this leaves 
the outer leaflet with very little net charge which sPLA2 should disfavor because of the ring 
of cationic residues on its interfacial binding surface (16).  Based on the annexin-V binding 
experiment we performed, PS was definitely exposed on the treatment cells so the IIA 
enzyme should have preferentially bound to the early apoptotic cells because of the 
increased exposure of PS.  The IIA enzyme is known to have a low affinity for the plasma 
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membrane of normal host cells because of the zwitterionic nature of their outer monolayer 
(21).  When this happens there are lower rates of membrane hydrolysis observed, as seen 
in Figure 10.  A recent study has shown that the rod domain of vimentin, a type III 
intermediate filament protein, is externalized in early apoptotic cells during the same time 
as PS exposure.  Vimentin creates a receptor for IIA in a calcium independent manner (23). 
This concludes that IIA is most likely not binding to phosphatidylserine alone and if it is, it 
does not play a major role in trapping the enzyme on the cell surface.
Though there were negligible differences between rates of hydrolysis seen when 
IIA culture supernatant was incubated with treatment and control cells, IIA was able to 
produce a chemoattractant that induced THP-1 monocyte chemotaxis (Figure 11).  There 
was a dose dependent increase in the number of THP-1 monocytes that migrated from the 
upper chamber the lower transwell chamber as the volume of chemoattractant in lower 
chamber increased.  Comparison of migration of THP-1 cells with no chemoattractant 
versus the migration of cells with three hundred microliter chemoattractant in the lower 
chamber showed a 24 fold increase in the number of migrated cells.  However, there was 
still no significant difference noted between untreated or early apoptotic Jurkat cells ability 
to generate chemoattractants.  When compared to MCP-1 there was no significant 
difference in the population of THP-1 monocytes that migrated when compared to treated 
and untreated cells incubated with culture supernatant. (Figure 12).  This suggests that 
when sPLA2 IIA binds to treated or untreated cells, they both produce chemoattractants 
that are just as effective as MCP-1.  Jurkat cells are known to contain about forty percent 
PC on the outer leaflet of their plasma membrane.  LPC could possibly be generated by 
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sPLA2 via catalytic hydrolysis of phosphatidylcholine (6).  LPC is generated upon 
phospholipase A2 mediated hydrolysis of membraneous phosphatidylcholine into LPC and 
a fatty acid such as arachidonic acid (6).  To determine if catalytic activity was required for 
monocyte chemotaxis, IIA culture supernatant was catalytically inactivated with para-
bromophenacylbromide (BPB) and added to live cells to produce a possible 
chemoattractant.   Upon catalytic analysis, BPB inhibited the catalytic activity of IIA 
(Figure 13). Hydrolysis of substrate phospholipids via sPLA2 proceeds through the 
activation and orientation of a water molecule by hydrogen bonding to the active site 
histidine, which dictates the pH dependence of 7-9 for all PLA2’s with a catalytic histidine 
(8).  sPLA2 completely loses its catalytic activity when the imidazole side chain of 
histidine 53 is alkylated through the reaction with BPB.  BPB is a selective inhibitor of 
sPLA2 only, so catalytic activity can possibly be attributed to the activation of caspase-3. 
Caspase-3 has been found to be required for the release of lysophosphatidycholine from 
the subsequent activation of iPLA2 though catalytic activity can be exerted via iPLA2 and 
cPLA2 without caspase activation (17).  Monocyte chemotaxis was found to be independent 
of sPLA2 activity. THP-1 monocytes were able to migrate to chemoattractants regardless of 
enzymatic activity; suggesting that the enzyme may stimulate Jurkat cells to produce 
chemoattractants through binding to heparan sulfate proteoglycans or other cell surface 
receptors (Figure 14).  The addition of heparinase to Jurkat cells before they are treated 
with IIA culture supernatant shows a decrease in the ability of IIA to exert catalytic 
activity when compared to the control. This suggests heparan sulfate proteoglycans 
possibly act as a receptor to trap the enzyme on the Jurkat cell surface.  When these 
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receptors are cleaved (done with heparinase), the sPLA2 has no receptor to bind which 
means it can no longer access the phospholipids located on the cell surface or internally 
and hydrolyze them (Figure 15).  Based on our results from our experiments we can 
conclude sPLA2 most likely associates with cells through interactions with heparan sulfate 
proteoglycans or another type of receptor.  Additional experiments are necessary to 
confirm lack of chemoattractant production in heparinase treated cells.
Heparan sulfate proteoglycans participate in many events during cell adhesion, 
migrations, proliferation, and differentiation (24). Cell surface heparan sulfate 
proteoglycans typically contain N linked and O linked oligosaccharides as carbohydrate 
components.  They are primarily localized in the plasma membranes or basement 
membranes.  HSPG such as glypican, decorin, and versican, are associated with the plasma 
membrane via direct intercalation of the core protein into the lipid bilayer, intercalation 
through a glycosylphosphatidylinositol (GPI) anchor covalently bound to a core protein, or 
specific or relatively nonspecific interactions between heparan sulfate chains and other 
molecules associated with the plasma membrane.  Glypican, is anchored to the external 
surface of the plasma membrane via GPI.  Heparan sulfate chains such as the three seen on 
glypican, are highly negative which determine their interactions with extracellular ligands 
(15).  Following binding of the highly anionic HSPG to the highly cationic IIA sPLA2, 
there are a number of endocytic routes available to allow internalization of the enzyme. 
IIA can be internalized via clathrin mediated endocytosis or caveolae mediated endocytosis 
where the enzyme is allowed to produce biological responses(21).  Based on observations 
of experiments done by Birts and his colleagues, the IIA enzyme is able to be taken up by 
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activated human THP-1 cells in an energy dependent process that relies on HSPG and 
involves macropinocytosis.  Uptake of the enzyme does not require the enzyme to be 
active, which could explain why BPB treated and untreated enzymes produced 
chemoattractants with similar migration percentages.  Birts also discovered the enzyme 
accumulates to the nucleus and is also able to bind and aggregate anionic phospholipids 
vesicles enhancing its uptake (21, 23). sPLA2 IIA has been found to accumulate in the 
caveolae and perinuclear sites, rather than being distributed uniformly on the cell surfaces 
as previously thought when associating with heparan sulfate chains of the GPI anchored 
HSPG glypican (3, 24).  After IIA is sorted into different compartments (via HSPG 
shuttling pathway), the enzyme is concentrated into the restricted compartments which 
allows for a spatial and temporal colocalization with perinuclear arachidonic acid 
metabolizing enzymes such as the overexpressed cyclooxygenase, COX-2 and 5-
lipoxygenase for efficient eicosanoid production (3).  Murakami, found via confocal 
microscopy, that after IIA is internalized, there may be perinuclear hydrolysis of 
membrane phospholipids.  If there is in fact hydrolysis of membrane phospholipids, the 
products produced would definitely provide chemoattractants such as LPC, LPA., and AA. 
Secretory phospholipase A2 could also bind to its probable heparan sulfate receptor and 
induce production of a protein chemokine such as monocyte chemotactic protein-1.  If IIA 
is colocalized with COX-2 the eicosanoids produced are also important stimulators for cell 
migration (24).  Boilard noted, that when he added heparin and heparinase to apoptotic 
cells, IIA binding was only partially inhibited, suggesting that there were other binding 
proteins involved with sPLA2 allocation on cell surfaces besides heparan sulfate 
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proteoglycans (18). 
  sPLA2 is able to interact with external cell membranes through direct binding to 
phospholipids or specific cell surface receptors (23).  Human high affinity cell surface 
receptors for the human group IIA enzyme have yet to be identified (21) but the interaction 
of IIA with the M type receptor is proposed as the main mechanism of action explaining 
the effects of IIA in mast cells and macrophages.  The M type receptor is a novel 
membrane bound protein found in skeletal muscles with structural organization similar to 
the C-type multilectin mannose receptor family (22).  The domain of the M type receptor 
that is responsible for sPLA2 binding, is the carbohydrate recognition domain 5. An M-type 
receptor where all CRD’s but CRD5 have been deleted can still bind sPLA2 with great 
affinity (22).  Since this has only been found using mouse IIA sPLA2, this suggests all 
receptors have not been characterized.  Like HSPG, a common property of the C-type 
multilectin mannose receptor family is endocytosis; and it has been proposed that the 
physiological role for the M type sPLA2 receptor is to internalize and deliver the sPLA2 
group  IIA to specific compartments within the cell where the enzyme may exert its 
activity (12).  Our usage of heparinase blocks most of our monocyte chemotactic activity, 
suggesting that there may not actually be a need for an additional receptor.
Our studies have shown that sPLA2 is able to bind both apoptotic and non apoptotic 
cells in the same fashion, creating a potent supernatant that attracts THP-1 monocytes 
regardless of catalytic activity.  Cleavage of heparan sulfate proteoglycans on cells applied 
with exogenous IIA sPLA2 prevent sPLA2 from binding and exerting catalytic activity, 
suggesting HSPG play an important roll in trapping a pool of the enzyme.  sPLA2 
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definitely plays a role in monocyte chemotaxis, but it has yet to be established if it does 
this by direct interaction with monocytes, indirectly via interaction with intracellular 
pathways, or both.  Phagocytosis requires multiple signals from apoptotic cells and these 
studies show sPLA2 have importance in producing these signals.  Since IIA applied to non 
apoptotic cells was found to also produce chemoattractants, this could prove to be an 
important factor in dealing with cancer cells and their subsequent removal.   In future 
studies, we will try to identify specific IIA receptors and see is HSPG is required for 
monocyte chemotaxis.
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